NantHealth saw its stock price close down 23 percent on Monday, on the heels of a report from STAT showing how Dr. Patrick Soon-Shiong used philanthropy to boost his health technology company.
As investors soured on the stock, a health care analyst defended the company and a law firm put out a call for participants in a potential class action investor suit.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Wouldn’t surprise me to see NantHealth’s lawyers to come after STATnews (even if just a sort of SLAPP reprisal action). Hope the article was fully legally vetted prior to publication.